Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) has commenced a phase III trial to test the long-term safety and effectiveness of its Grass MATA MPL allergy treatment in children.
This marks the first industry trial of its kind for paediatric patients with grass pollen-induced allergic rhinitis.
Grass MATA MPL uses an innovative formula that includes microcrystalline tyrosine and monophosphoryl-lipid A, requiring just six doses before the grass allergy season.
The treatment aims to reduce allergy symptoms and the need for medication.
The paediatric trial follows the successful phase III G306 trial in adults, where Grass MATA MPL showed significant reductions in allergy symptoms compared to a placebo.
Results from that study supported a regulatory application to Germany's Paul Ehrlich Institut.
This latest trial aims to determine whether the treatment is safe and effective for children over the long term. If successful, it could expand options for managing grass pollen allergies in younger patients.
"The start of the Phase III G308 trial investigating the efficacy and safety of our Grass MATA MPL in a paediatric population marks an exciting step in bringing this innovative treatment to further patients affected by grass allergies," said Manuel Llobet, CEO of Allergy Therapeutics.
"Building on our successful adult trials, this study will help us understand how our short-course immunotherapy can benefit children affected by grass allergies, potentially transforming their treatment journey."